 novel anti-complement proteins. Proteins produced by ticks are attractive vaccine targets because such vaccines have the potential to block tick feeding and pathogen transmission. Under aim 3 we plan to test anti-complement proteins as vaccines that block feeding and/or pathogen transmission. Our industry partner in these studies is L2 diagnostics, which
novel anti - complement proteins. Proteins produced by check mark are attractive vaccine target because such vaccines have the potential to obstruct tick feeding and pathogen infection. Under bearing 3 we plan to screen anti - complement proteins as vaccines that stop feeding and/or pathogen transmission. Our industry partner in these studies is L2 diagnostics, which
 nogel anti-complement protelns. Proteins probyced bb ticks are attfactive vaccine targets becanse wuch caccines have the potevtial to hlock tixk fteding and pathogxh transmissioh. Undzr aim 3 we plan jo test anti-womplement prodeknd as vaccines that block feeding anq/or patnohen transmissijn. Olr indhstry partner in these studies is M2 diagnmstics, which
novel anti-complement proteins. Proteins produced by ticks vaccine because such have the potential pathogen Under aim 3 plan to test proteins as vaccines that block feeding pathogen transmission. Our industry partner in these studies is L2 diagnostics, which
 novel anti-complement proteiNs. Proteins ProduCed By tIcKs arE attRactive vaccine TArgeTs because such vaccines hAve thE pOTentIAl To bloCk tick fEEdING anD pAtHogEn TRaNsmisSioN. Under aIm 3 we plan to TesT aNti-complemenT PrOteins as vaCciNes that block FeeDing anD/oR paTHogen TraNsmisSion. OuR IndustRy partner In THese stUDies is L2 DIAgNostIcs, which
 novel anti-complement pro teins. Pro teins  pr odu ce d by  tic ks are attract i ve v accine targets because  such  v a ccin e shavethe pot e nt i a l t obl ock  t i ck  feed ing  and pa thogen tra nsm is sion. Undera im  3 we plan  to  test anti-c omp lement  p rot e ins a s v accin es tha t  block  feedingan d /or pa t hogen t r a ns miss ion. Our industry pa r tner in thesestudie si sL 2  di agn ostics, wh ic h
 novel_anti-complement proteins._Proteins produced by ticks_are attractive_vaccine_targets because_such_vaccines have the_potential to block_tick feeding and pathogen_transmission. Under aim_3_we plan to test anti-complement proteins as vaccines that block feeding and/or pathogen transmission._Our_industry partner_in_these_studies is L2 diagnostics, which